MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- PANACEA BIOTECH - CIPLA
PANACEA BIOTECH vs CIPLA - Comparison Results
PANACEA BIOTECH Change
Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More
CIPLA 
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Current Valuations
| PANACEA BIOTECH | CIPLA | PANACEA BIOTECH/ CIPLA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 12.2 | 23.7 | 51.5% | View Chart |
| P/BV | x | 2.9 | 2.4 | 121.0% | View Chart |
| Dividend Yield | % | 0.0 | 0.7 | - |
Financials
 PANACEA BIOTECH  CIPLA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| PANACEA BIOTECH Mar-18 |
CIPLA Mar-19 |
PANACEA BIOTECH/ CIPLA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 364 | 678 | 53.7% | |
| Low | Rs | 129 | 484 | 26.7% | |
| Sales per share (Unadj.) | Rs | 96.8 | 198.2 | 48.8% | |
| Earnings per share (Unadj.) | Rs | -12.4 | 18.5 | -67.0% | |
| Cash flow per share (Unadj.) | Rs | -2.9 | 35.0 | -8.2% | |
| Dividends per share (Unadj.) | Rs | 0 | 3.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.5 | 0.0% | |
| Book value per share (Unadj.) | Rs | 50.4 | 186.3 | 27.0% | |
| Shares outstanding (eoy) | m | 61.25 | 805.70 | 7.6% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 2.5 | 2.9 | 86.9% | |
| Avg P/E ratio | x | -19.9 | 31.4 | -63.4% | |
| P/CF ratio (eoy) | x | -86.4 | 16.6 | -520.6% | |
| Price / Book Value ratio | x | 4.9 | 3.1 | 156.9% | |
| Dividend payout | % | 0 | 16.2 | 0.0% | |
| Avg Mkt Cap | Rs m | 15,101 | 468,031 | 3.2% | |
| No. of employees | `000 | 2.5 | 22.6 | 10.9% | |
| Total wages/salary | Rs m | 1,516 | 28,565 | 5.3% | |
| Avg. sales/employee | Rs Th | 2,401.9 | 7,053.1 | 34.1% | |
| Avg. wages/employee | Rs Th | 614.2 | 1,261.5 | 48.7% | |
| Avg. net profit/employee | Rs Th | -307.9 | 659.1 | -46.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,928 | 159,710 | 3.7% | |
| Other income | Rs m | 82 | 4,766 | 1.7% | |
| Total revenues | Rs m | 6,010 | 164,475 | 3.7% | |
| Gross profit | Rs m | 845 | 30,973 | 2.7% | |
| Depreciation | Rs m | 585 | 13,263 | 4.4% | |
| Interest | Rs m | 1,006 | 1,684 | 59.7% | |
| Profit before tax | Rs m | -664 | 20,791 | -3.2% | |
| Minority Interest | Rs m | 0 | -172 | 0.0% | |
| Prior Period Items | Rs m | 2 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 99 | 5,695 | 1.7% | |
| Profit after tax | Rs m | -760 | 14,924 | -5.1% | |
| Gross profit margin | % | 14.3 | 19.4 | 73.5% | |
| Effective tax rate | % | -14.9 | 27.4 | -54.3% | |
| Net profit margin | % | -12.8 | 9.3 | -137.2% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 5,603 | 124,266 | 4.5% | |
| Current liabilities | Rs m | 6,910 | 37,715 | 18.3% | |
| Net working cap to sales | % | -22.0 | 54.2 | -40.7% | |
| Current ratio | x | 0.8 | 3.3 | 24.6% | |
| Inventory Days | Days | 206 | 91 | 227.1% | |
| Debtors Days | Days | 84 | 95 | 88.3% | |
| Net fixed assets | Rs m | 9,941 | 105,190 | 9.5% | |
| Share capital | Rs m | 61 | 1,611 | 3.8% | |
| "Free" reserves | Rs m | 3,026 | 148,511 | 2.0% | |
| Net worth | Rs m | 3,087 | 150,123 | 2.1% | |
| Long term debt | Rs m | 5,707 | 38,301 | 14.9% | |
| Total assets | Rs m | 16,076 | 239,633 | 6.7% | |
| Interest coverage | x | 0.3 | 13.3 | 2.6% | |
| Debt to equity ratio | x | 1.8 | 0.3 | 724.7% | |
| Sales to assets ratio | x | 0.4 | 0.7 | 55.3% | |
| Return on assets | % | 1.5 | 6.9 | 22.1% | |
| Return on equity | % | -24.6 | 9.9 | -247.7% | |
| Return on capital | % | 3.9 | 11.8 | 33.1% | |
| Exports to sales | % | 24.0 | 34.7 | 69.2% | |
| Imports to sales | % | 17.5 | 0 | - | |
| Exports (fob) | Rs m | 1,424 | 55,419 | 2.6% | |
| Imports (cif) | Rs m | 1,040 | NA | - | |
| Fx inflow | Rs m | 1,600 | 57,410 | 2.8% | |
| Fx outflow | Rs m | 1,131 | 19,041 | 5.9% | |
| Net fx | Rs m | 469 | 38,368 | 1.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,180 | 16,911 | 7.0% | |
| From Investments | Rs m | 553 | -16,687 | -3.3% | |
| From Financial Activity | Rs m | -1,644 | -3,487 | 47.1% | |
| Net Cashflow | Rs m | 90 | -3,451 | -2.6% | |
Share Holding
| Indian Promoters | % | 74.5 | 16.0 | 465.6% | |
| Foreign collaborators | % | 0.0 | 20.8 | - | |
| Indian inst/Mut Fund | % | 0.6 | 12.2 | 4.9% | |
| FIIs | % | 1.3 | 23.7 | 5.5% | |
| ADR/GDR | % | 0.0 | 1.1 | - | |
| Free float | % | 23.6 | 26.2 | 90.1% | |
| Shareholders | 10,259 | 161,166 | 6.4% | ||
| Pledged promoter(s) holding | % | 35.1 | 0.0 | - |
Compare PANACEA BIOTECH With: ASTRAZENECA PHARMA ALEMBIC PHARMA CADILA HEALTHCARE NOVARTIS DR. DATSONS LABS
Compare PANACEA BIOTECH With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)
Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.
Related Views on News
CIPLA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 9, 2019 | Updated on Sep 9, 2019Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)
May 24, 2019 | Updated on May 24, 2019For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)
Mar 27, 2019 | Updated on Mar 27, 2019Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.
PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.
More Views on NewsMost Popular
Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
A Recession Proof Stock You Can Bet On(Profit Hunter)
Sep 10, 2019Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.
A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)
Sep 16, 2019The stock market today is throwing up a great opportunity to pile on quality stocks.
This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)
Sep 11, 2019How financial inclusion provides a big runway for this stock recommendation.
The 5 Best Trading Opportunities I've Spotted(Profit Hunter)
Sep 13, 2019These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.
MorePANACEA BIOTECH SHARE PRICE
Sep 19, 2019 (Close)
TRACK PANACEA BIOTECH
- Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PANACEA BIOTECH
PANACEA BIOTECH 5-YR ANALYSIS
COMPARE PANACEA BIOTECH WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.